AKT1 and malignant peripheral nerve sheath tumor: This study reports potent inhibition of proliferation in dedifferentiated-LPS and MPNST cell lines upon sitravatinib treatment, with associated blockade of PDGFRβ, MET, and insulin-like growth factor 1 receptor (IGF1R) phosphorylation, as well as downstream AKT signaling [19].